Value Based Payment for Gene Therapy
ADVI helped develop an outcomes-based payment approach for a one-time, curative gene therapy manufacturer to use in reimbursement discussions with state Medicaid programs and commercial payers.
ADVI helped develop an outcomes-based payment approach for a one-time, curative gene therapy manufacturer to use in reimbursement discussions with state Medicaid programs and commercial payers. ADVI’s gene therapy experience spans 16 different manufacturers and 20 different therapeutic areas.
CEO insights
Related articles
Real analysis from people who’ve been there
CMMI Engagement on CGT Model
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.